Mitochondrial Fusion/Fission, Transport and Autophagy in Parkinson's Disease: When Mitochondria Get Nasty by Arduíno, Daniela M. et al.
SAGE-HindawiAccess to Research
Parkinson’s Disease
Volume 2011, Article ID 767230, 13 pages
doi:10.4061/2011/767230
Review Article
MitochondrialFusion/Fission,Transport andAutophagyin
Parkinson’sDisease: WhenMitochondria Get Nasty
Daniela M. Ardu´ ıno,1 A.RaquelEsteves,1 andSandraM. Cardoso1,2
1Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Largo Marquˆ es de Pombal,
3004-517 Coimbra, Portugal
2Faculty of Medicine, University of Coimbra, Largo Marquˆ es de Pombal, 3004-517 Coimbra, Portugal
Correspondence should be addressed to Sandra M. Cardoso, smacardoso@yahoo.com
Received 1 October 2010; Revised 26 November 2010; Accepted 5 January 2011
Academic Editor: Charleen T. Chu
Copyright © 2011 Daniela M. Ardu´ ıno et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
UnderstandingthemolecularbasisofParkinson’sdisease(PD)hasproven to be amajorchallengein theﬁeldofneurodegenerative
diseases. Although several hypotheses have been proposed to explain the molecular mechanisms underlying the pathogenesis of
PD, a growing body of evidence has highlighted the role of mitochondrial dysfunction and the disruption of the mechanisms
of mitochondrial dynamics in PD and other parkinsonian disorders. In this paper, we comment on the recent advances in
how changes in the mitochondrial function and mitochondrial dynamics (fusion/ﬁssion, transport, and clearance) contribute
to neurodegeneration, speciﬁcally focusing onPD. Wealsoevaluatethecurrent controversies in thoseissuesand discussthe role of
fusion/ﬁssiondynamics in the mitochondrial lifecycle and maintenance. We propose that cellular demise and neurodegeneration
in PD are due to the interplay between mitochondrial dysfunction, mitochondrial traﬃckingdisruption, and impaired autophagic
clearance.
1.Introduction:The CriticalRoleof
Mitochondrial DysfunctioninPD
The intrinsic properties of mitochondria make them essen-
tial integrators of cellular functions. These organelles are
critical as ATP suppliers, calcium buﬀers and transducers
of intracellular signaling pathways which integrate pro-
grammed cell death. Therefore, mitochondrial function has
a critical role in the brain physiology, where the impaired
functioning of mitochondria has been implicated in several
neurological disorders, like Parkinson’s disease (PD).
PD is a chronically progressive, age-related neurode-
generative disease, clinically characterized by progressive
resting tremor, rigidity, bradykinesia, gait disturbance, pos-
tural instability, and dementia. A major neuropathologi-
cal hallmark of PD is the degeneration of dopaminergic
neurons in the substantia nigra pars compacta (SNpc) and
in other brainstem regions. A second neuropathological
feature is the presence of intracytoplasmic inclusions (Lewy
bodies, LBs) in surviving neurons, which comprise a dense
core of diﬀerent proteins as α-synuclein, parkin, ubiquitin,
synphilin-1, tubulin, and other cytoskeletal proteins [1].
Over the last several decades, a growing body of evidence
accumulated focusing on the crucial role of mitochondria
and mitochondrial dysfunction in PD etiopathogenesis [2–
6].
The most compelling evidence of mitochondrial dys-
function in PD emerged following the human accidental
exposure to the synthetic meperidine analogue 1-methyl-
4-phenyl-1,2,3,6-tetrahydrodropyridine (MPTP) which in-
duced a parkinsonian syndrome through a decrease in
complex I activity by its metabolite 1-methyl-4-phenylpyr-
idinium (MPP+)[ 7, 8].
Furthermore, mitochondrial association with idiopathic
PD was ﬁrst established when a mitochondrial NADH
dehydrogenase (complex I) activity deﬁcit was identiﬁed
in the SNpc of postmortem PD patients brains [9]a n d
in PD patients platelets [10]. Further evidence suggested a
similar complex I deﬁciency in PD patients lymphocytes [11,
12], although few reports failed to demonstrate consistent2 Parkinson’s Disease
changes between PD and control cells [13]. To address
the potential causes of complex I defect, that is, if it
was due to an environmental toxin or to an alteration
of mitochondrial or nuclear DNA, the cytoplasmic hybrid
technique has been used. This approach consists on the
transfer of sporadic PD subject platelet mitochondria to
mtDNA-depleted cells, generating hybrid lines (cybrids).
In this way, it is possible to follow the expression of the
mitochondrial mutations and the eﬀects of its heteroplasmy
in a wild-type nuclear DNA environment. A stable decrease
in complex I activity, increased reactive oxygen species
(ROS) production, proton leak, and decreased maximum
respiratory capacity were described in PD cybrids [14–17].
All of these features are consistent with the involvement
of respiratory chain dysfunction in PD. In addition to
mtDNAmutations,theproductsoffamilial PD-linkedgenes,
including α-synuclein, parkin, DJ-1, PINK1 (PTEN-induced
kinase 1),LRRK2(Leucine-rich repeatkinase 2),were shown
to locate in or interact with mitochondria under certain
conditions[18,19].Inaddition,lossofOMIproteaseactivity
increases the susceptibility of mitochondria to induce the
permeability transition [20]. Moreover, LRRK2 colocalizes
with the mitochondrial outer membrane [21]a n dm a y
r e g u l a t et h er e s p o n s et om i t o c h o n d r i a li n h i b i t o r s[ 22].
Other studies revealedmany novel proteins with quantitative
expression diﬀerences in PD when compared to controls.
Those include subunits of complex I, mitochondrial creatine
kinase, the chaperone mortalin (mthsp70/GRP75), and
glutathione s-transferase pi, all proteins implicated in mito-
chondrial functions and cellular responses to oxidative stress
[23, 24].
This body of evidence is suggestive that mitochondrial
function is altered in PD. In this paper we will focus
on mitochondrial dynamics, emphasizing the changes in
mitochondrial motility and mitochondrial quality control
mechanisms, critical to maintain mitochondrial function
and cellular homeostasis. Moreover, we will also address the
contributions of these topics to cellular demise associated
to PD neurodegeneration and comment on the current
controversies that exist on this issue.
2.Mitochondrial Dynamics and PD
2.1. Mitochondrial Dynamics. Mitochondria can appear as
discrete tubules or interconnected networks in living cells
[25]. This range on mitochondrial shaping and size proﬁles
is continuous since the hundreds of mitochondria within a
cell can undergo frequent cycles of fusion (the combination
of two mitochondria into a single organelle) and ﬁssion (the
separation of long, tubular mitochondria into two or more
smaller parts) [26, 27]. This fusion/ﬁssion dynamics is very
important in maintaining the functional integrity of mito-
chondria as the constituents of each network share solutes,
metabolites, and proteins [28–30], as well as electrochemical
gradient, making them electrically coupled [31, 32]. These
mitochondrial networks characteristics suggest that fusion is
a mechanism required forthe properrespiratory activity and
metabolic eﬃciency ofmitochondria, as well as, for thecom-
plementation, stabilization, and protection of mitochondrial
DNA (mtDNA) [33, 34]. Actually, the functionality of a
damaged mitochondria can be complemented by fusion
with a neighboring integral mitochondria and possibly be
restored [26]. In addition, the transfer of mtDNA or whole
mitochondria between cells can occur in vitro and rescue
aerobic respiration in cells without functional mitochondria
[35].
Both mitochondrial ﬁssion and fusion seem to be
required to maintain mitochondrial function. However,
the mechanisms diﬀer. Fission occurs probably to protect
function by facilitating equal segregation of mitochondria
into daughter cells during cell division and to improve
distribution of mitochondria along microtubules tracks. In
addition, ﬁssion may also help to isolate segments of dam-
aged mitochondria, promoting their clearance by macroau-
tophagy as discussed below [36]. Besides to maintain normal
m i t o c h o n d r i a lf u n c t i o n s ,m i t o c h o n d r i a lf u s i o n ,a sw e l la s
mitochondrial ﬁssion have also been associated with cell
death/survival mechanisms [37, 38].
Sophisticated genetic and biochemical studies in sev-
eral organisms, ranging from Drosophila melanogaster and
baker’s yeast Saccharomyces cerevisiae to mammalian cells,
have provided valuable inroads into understanding the
biological processes of mitochondrial dynamics and greatly
accelerated the identiﬁcation and characterization of the
major components of the fusion and ﬁssion machineries
and their regulation [39–42]. The critical balance between
mitochondrial dynamic systems is greatly maintained by
a large group of conserved proteins, the dynamin-related
GTPases.
2.2. Mitochondrial Fusion. Mitochondrial fusion involves
mechanisms distinct or at least more complex from those
that govern membrane fusion in the secretory pathway
or other membrane-bound organelles. The fusion process
can be divided in at least three events: docking, fusion of
the outer membrane, and fusion of the inner membrane.
Mitofusins Mfn1 and Mfn2 are engaged in mitochondria
tethering and outer membrane fusion. Opa1 is involved in
the outer membrane fusion step with the inner membrane
contacts and can have a direct physical contribution to the
fusion of inner membranes itself [43]. Moreover, it has
been described that mutations in Opa1 and Mfn2 genes
cause Kjer’s disease/autosomal dominant optic atrophy and
C h a r c o t - M a r i eT o o t ht y p e2 An e u r o p a t h yi nh u m a n s[ 44].
To date, several mechanisms, such as protein-protein
interactions, posttranslational modiﬁcations, protein turn-
over and the lipid environment, have been proposed as
regulators of mitochondrial fusion. Indeed, the modulation
of the amount of Mfn protein regulates the extent of
mitochondrial fusion. In addition, the ability of Mfn1
and 2 to oligomerize and hydrolyze GTP to promote the
membrane rearrangements is another point of regulation
of mitochondrial fusion [45]. The mechanism of inner
membrane fusion is unknown, but ﬁndings indicate that
two distinct isoforms of Opa1, resulting from proteolytic
processing,arenecessary forsuccessfulfusionevents[46,47].
Two mammalian members of proapoptotic Bcl-2 family
members, Bax and Bak, induce mitochondrial fusion byParkinson’s Disease 3
regulating the assembly and submitochondrial distribution
of Mfn2. Intriguingly, their mitochondrial localization is
required for apoptosis induction and for cell survival, point-
ing to an intimate connection of mitochondrial remodeling
and programmed cell death [48].
2.3. Mitochondrial Fission. While the precise mechanism
of mitochondrial ﬁssion in mammals is largely unknown,
most insights concerning this mechanism have come from
studies in yeast. It is thought that mitochondrial ﬁssion in
mammalsfollowsthesamestepsasinyeast:Drp1isrecruited
to mitochondria, and constriction of the membranes takes
place via direct or indirect interaction with hFis1 [49].
The major regulatory mechanisms that control mito-
chondrial ﬁssion seem to involve posttranslational modiﬁ-
cations of Drp1 which determine its localization, dynamics,
and activity. One of the posttranslational modiﬁcations that
regulate mitochondrial division is ubiquitinylation. Drp1
ubiquitinylation seems to regulate the kinetics of Drp1
binding tothe mitochondrial surface. Thus, ubiquitinconju-
gation might regulate the subcellular traﬃcking, assembly of
D r p 1 ,a n di n ﬂ u e n c et h er a t eo fm i t o c h o n d r i a ld i v i s i o n[ 50].
Mitochondrial ﬁssion is also regulated in part by phosphory-
lation. It was demonstrated that phosphorylation of Drp1 at
serine 616 by the cyclin B-dependent kinase (CDK1)induces
fragmentation of mitochondria during mitosis [51]. Unlike
phosphorylation by CDK1, protein kinase A-(PKA, cAMP-
dependent protein kinase-) dependent phosphorylation of
ad i ﬀerent serine residue (S637) can decrease Drp1 GTPase
activity [52]. Thus, it seems that phosphorylation of Drp1
by diﬀerent kinases at diﬀerent amino acid residues causes
oppositeeﬀects.AlthoughtheinitialstudyindicatethatDrp1
phosphorylation can modulate the frequency of mitochon-
drial division, it remains to be understood if the ﬁssion
competent phospho-Drp1 (S616) is always phosphorylated
by CDK1 or if this mechanism is only active during the
cell cycle [39]. Moreover, dephosphorylation of S637 by
theCa2+-dependentphosphatase calcineurinpromotesDrp1
translocation to mitochondria and subsequently mitochon-
drial ﬁssion [53].
In addition to frequent cycles of fusion and ﬁssion in a
“kiss and run” pattern, mitochondria are also turned over
during the neuronal lifetime, being replaced throughout
organelle biogenesis.
2.4.Mitochondrial Biogenesis. Mitochondria cannotbemade
de novo. The formation of new mitochondria, called mito-
chondrial biogenesis, encompasses all processes involved in
maintenance and growth of these organelles, as well as the
ones required for their division and segregation during the
cell cycle. Thus, mitochondrial biogenesis is an extremely
complex process that requires the synthesis, import, and
incorporation of proteins and lipids to the existing mito-
chondrial reticulum, as well as the replication of the
mtDNA. Although mitochondria have their own DNA,
mitochondrial genome encodes only a small but essential
group of 13 proteins, including hydrophobic proteins of the
electron transport chain, as well as mitochondrial tRNAs
and rRNA. The vast majority of the mitochondrial proteins
are encoded by nuclear genes. Therefore, mitochondrial
biogenesis requiresthe coordinated transcription ofthe large
number of mitochondrial genes in the nucleus, as well
as of the fewer but essential genes in mitochondria. This
implies the cooperation of two genomes, which is a potential
challengetotheneuronalcell.Thiscouldlimitmitochondrial
biogenesis to the cell body and require that all mitochondrial
renewal in the distal axon occurs by axonal transport.
However, there is also a reason to believe that mitochondrial
biogenesis could occur within the axon. It is now well
established that local protein synthesis occurs in axons [54–
56] and is essential for axonal functions including direction
[57–59], regeneration [56, 60–62], and maintenance of
mitochondrial membrane polarization [63]. In addition,
transcripts for nuclear-encoded mitochondrial proteins are
amongthespeciesfoundinaxons[64].Moreover,mitochon-
dria are found in close proximity to translation sites in the
axon [65]. Several studies have revealed that components of
the mitochondrial replication apparatus are located outside
the perinuclear region in nonneuronal cells [66–70]a n d
in SH-SY5Y neuron-like cells [70]. More recently, it was
shown that mtDNA replication and mitochondrial ﬁssion
and fusion occur in the distal axons of peripheral neurons in
culture, showing that a portion of mitochondrial biogenesis,
likeproteinbiosynthesis, doesoccurintheaxonatsigniﬁcant
distances from the cell body [71].
2.5. The Relevance of Mitochondrial Dynamics for Neuronal
Integrity. Neurons are highly specialized cells that undergo
unique challenges in carrying out their important physi-
ological functions. First, neurons are active cells and thus
requirelargeamounts ofenergy.Furthermore,someneurons
have extremely long processes, with axons extending up to
one meter in motor neurons. Thus, neurons must transmit
energy across long distances. They are also long-lived
postmitoticandhighlyinteractivecellswhosemajorfunction
is communication. Therefore, neurons rely profoundly on
the rapid and versatile distribution of mitochondrial activity
and on mitochondrial biogenesis over the time and space
[72].Inneurons,themitochondrialﬁssion/fusion machinery
is intimately and critically involved in the formation of
synapses and dendritic spines. Actually, both fusion and
ﬁssion mechanisms contribute for the full-mitochondrial
lifecycle and any disruption on their balance could change
the steady-state distribution of mitochondrial span. Since
mitochondria cannot be made de novo, the ﬁssion of
preexisting organelles is essential for generation of the new
mitochondria. Distressing ﬁssion or fusion mechanisms
either by inhibiting expression of the ﬁssion protein Drp1
[73–75] or by overexpressing the fusion protein Mfn1 [76]
has been shown to prevent mitochondria from distributing
to synapses, leading to a loss of mitochondria from den-
dritic spines and, consequently, to a reduction of synapse
formation. On the other hand, counteracting this process
by overexpressing Drp1 and/or promoting its eﬀects on
dendritic mitochondria restores synapse formation [77]. In
addition, mitochondrial fusion has been directly implicated
inpreventingtheaccumulationofdamagedmtDNA[28,78].
More recently, mitochondrial ﬁssion has also been shown4 Parkinson’s Disease
to be critical to mtDNA maintenance [79]. Accordingly,
it seems that ﬁssion and fusion serve the same purposes
along neurons: ﬁssion is the ﬁnal step in mitochondrial
duplication, whereas fusion dilutes errors in mtDNA, being
both processes required to protect mitochondrial integrity
and function [30, 80].
Thus, considering how much neurons depend on mito-
chondria, it should come as no surprise that there is a
strong association between mitochondrial dysfunction and
neurodegenerative diseases. However, key questions arise:
why speciﬁc areas of the brain are diﬀerentially aﬀected?
and/orwhy only selective groupsofneurons dieinPD?What
makes these speciﬁc groups of distinct neurons particularly
susceptible to degeneration is not known yet. However,
it is now well established that the degeneration of PD
aﬀects not only dopaminergic neurons, but many other
neurons in the central nervous system, including popula-
tions in the brainstem, as well as in the subcortical and
cortical regions [81]. Neurons of these areas have common
features as they have long and thin axons, which have
little or no myelination [82]. Neurons with these features
are more vulnerable to degeneration and require high
energy demands and so they are particularly dependent on
suitable mitochondrial dynamics. In addition, it was recently
reported that mitochondrial mass and size are correlated
with cell size and that dopaminergic neurons in the SNpc,
ventral tegmental area, and interfascicular nucleus have a
signiﬁcantly a smaller area of the cytoplasm occupied by
mitochondria than in the neighboring nondopaminergic
neurons. This suggests that the low mitochondria mass of
the nigral dopaminergic neurons may contribute to their
vulnerability to degeneration [83]. Moreover, mitochondrial
contentinaxons,synapses, anddendrites(collectivelyknown
as neurites) plays a crucial role in regulating outgrowth and
synaptic remodeling into adulthood [77, 84]. Alterations
on neurites remodeling and plasticity due to aging and
disease processes probably contribute to memory loss and
neurodegeneration. In fact, the dynamic remodeling of pre-
existing mitochondria may play a more prominent role than
biogenesis in regulating mitochondrial content in neuritis
[75, 85].
3.Novel Implicationsof Mitochondrial
Dynamics inPD Pathogenesis
3.1. Mitochondrial Motility: An On-Track Sliding-Dependent
Cellular Process. Proper functioning of mitochondria
depends on their intracellular location which is decisively
governed by aspects of mitochondrial spatial arrangement
and motility beyond fusion and ﬁssion. Those aspects are
critically important when we look to cell polarity, such as in
neurons [72], which require mitochondria at sites distant
from the cell body. Transport of mitochondria and their
positioning within neurons are microtubule-dependent and,
inturn,transport onmicrotubulesdependsonthemolecular
motors kinesins and dyneins [86]. It was demonstrated that
the dynein-dynactin motor complex interacts with Drp1
and recruits the protein to the mitochondrial surface [87].
In addition, disruption of F-actin also blocks translocation
of Drp1 and, subsequently, mitochondrial ﬁssion [88].
Very recently, Milton and Miro were shown to localize to
mitochondria in mammalian neurons and interact with
each other in vivo in the brain [89, 90]. Miro has also
been shown to bind directly to kinesin heavy chain KIF5
in a Ca2+-sensitive manner [89, 90] and together with
Milton (Miro-Milton complex) allows mitochondria to
move along the microtubule network and supports on-
demand distribution of mitochondria. In mammalian
cells, manipulation of Miro1 was shown to dramatically
aﬀect mitochondrial morphology and these eﬀects, in the
particular case of ﬁssion, appear to involve Drp1 activation
[91]. In Drosophila, loss of Miro-dependent transport
pathway results in depletion of mitochondria in dendrites
and axons, inducing neurotransmission defects during
prolonged stimulation [92]. Furthermore, defects in both
fusion and ﬁssion have been shown to impair mitochondrial
movement. Apparently, the large interweave of highly
connected mitochondria in ﬁssion-deﬁcient cells prevents
an eﬃcient movement, particularly into thin locations such
as neuronal processes [75, 77]. In fusion-deﬁcient cells, the
cause of decreased motility is less obvious. However, Mfn-
deﬁcient mitochondria display loss of directed movement,
travelling in a manner reminiscent of Brownian motion
[45]. In neurons lacking mitochondrial fusion, swollen
and nucleoid-deﬁcient mitochondria cluster at dendritic
junctions and are unable to enter the distal, smaller diameter
branches. Thus, both clustering of mitochondria in the cell
body and the blockage of eﬃcient entry into neurites may
contribute to the lack of mitochondria in the axons and
dendrites [37]. Collectively, pieces of evidence lead to the
hypothesis that the eﬀectofmitochondrial fusion and ﬁssion
disturbances could secondarily impair motility and, on the
other hand, transport defects aﬀect mitochondrial shape.
3.2.Mitophagy:AMajorLineofDefenseagainst Mitochondrial
Damage. As mentioned before, perturbations in mitochon-
drial dynamics, throughout fusion or ﬁssion alterations, can
impair the energy provision by mitochondria in mammalian
neurons. Nevertheless, cells have developed sophisticated
systems to deal with the diverse challenges imposed on
mitochondrial functional integrity. These systems could
comprise a “multistep” mitochondrial quality control net-
work that assists to the spatial segregation of damaged
mitochondria. The ﬁrst tier of quality control is provided by
both molecular chaperones and the intracellular proteolytic
system, which selectively remove excess and damaged pro-
teins from mitochondria outer membrane. A second step in
mitochondrial quality control could be mediated by fusion
of damaged mitochondria with neighboring mitochondria
[26]. However, severe injury of mitochondria impairs fusion
and further activates ﬁssion-dependent fragmentation and
sequestration by an autophagic process, termed mitophagy.
Accumulating data suggests that mitochondrial dysfunction
by itself triggers mitophagy[93]. In fact, it was demonstrated
that mitochondria-derived ROS, at low concentrations, may
act as signaling moleculesand trigger mitophagy throughout
redox regulation of Atg4, an essential cysteine protease
in the autophagic pathway [94]. Similarly, Gomes andParkinson’s Disease 5
Scorrano also provided evidence that the proﬁssion mito-
chondrial protein Fis1 induces mitochondrial fragmentation
and enhances mitophagy. Nevertheless, these changes were
correlated with mitochondrial dysfunction rather than with
fragmentation [95]. As well, mitochondrial ﬁssion was also
shown to be an important step for the autophagic clearance
of depolarized or damaged mitochondria, since overexpres-
sion of Drp1 promotes mitophagy [36].
Additional studies showed the involvement of Parkin,
PINK, and LRRK2 in the regulation of mitochondrial clear-
ance and homeostasis. Parkin was found to be selectively
recruited to dysfunctional mitochondria with low mem-
brane potential in mammalian cells targeting mitochondria
towards the autophagic-lysosomal pathway [96]. Moreover,
translocation ofParkin tomitochondria isvoltagedependent
and does not depend on changes in pH or ATP levels [97].
Thus, these ﬁndings suggest that Parkin may act as a sensor
for mitochondrial integrity and limit mitochondrial damage
byactinginapathwaythatidentiﬁesandeliminates damaged
mitochondria from the mitochondrial network.
P I N K 1a n dP a r k i nc a nc o o p e r a t ei nac o m m o np a t h -
way that is involved in the protection of mitochondrial
integrity and function. Indeed, it was reported that co-
overexpression of Parkin and PINK1 collapses the normal
tubular mitochondrial network into mitochondrial aggre-
gates and/or large perinuclear clusters, many of which are
associated to LC3-enriched autophagic vacuoles [98, 99].
These results suggest that both proteins are involved in
the modulation of mitochondrial traﬃcking, especially to
the perinuclear region, a subcellular area associated with
autophagy-lysosomal degradation [98]. Moreover, PINK1
accumulation on mitochondria is both necessary and suf-
ﬁcient for Parkin recruitment to mitochondria [98, 100].
Recent studies have shown that PINK1 accumulates selec-
tively on dysfunctional mitochondria and its kinase activity
together with its mitochondrial sequence is a prerequisite to
induce translocation of Parkin to depolarized mitochondria.
Subsequently, Parkin mediates the poly-ubiquitylation of
VDAC-1 (voltage-dependent anion channel 1) [101], Mfn1,
and Mfn2 among other mitochondrial proteins [102]. Addi-
tionally, the autophagic adaptor p62/SQSTM1 is recruited
to mitochondrial clusters and is essential for the clearance
of mitochondria by mitophagy [101]. Taken together, these
data provide a functional link between Parkin, PINK1 and
mitophagy which is implicated in the pathogenesis of PD.
Moreover, the role of LRRK2 in regulating autophagy
was also addressed. Interestingly, it was shown that LRRK2
speciﬁcally localizes to speciﬁc membrane subdomains and
endosomal-autophagic structures, suggesting a functional
relationship between LRRK2 and mitophagy [103]. More-
over, increased autophagic activity upon LRRK2 knockdown
was observed, which indicates that LRRK2 may normally
act as a negative regulator of autophagy [103]. Alterna-
tively, LRRK2 regulation in neurite blunting and remod-
eling requires autophagy [104]. Thus, by impairing this
pathway, mutations in Parkin, PINK1, and LRRK2 may
alter autophagy-dependent mitochondrial turnover which,
in turn, may cause the accumulation of defective mitochon-
dria and, ultimately, neurodegeneration in PD. Conversely,
Beclin 1-independent autophagy/mitophagy contributes to
cell death elicited by the PD toxins MPP+ and 6-OHDA
[105], causing neurite retraction in cells expressing the
G2019S PD-linked mutation in LRRK2 [105]. However,
excessive or incomplete autophagy without suitable regen-
erative biogenesis, due to deﬁcient retrograde traﬃcking of
vesicles can lead to “autophagic stress” [106], which may
ultimately lead to neuronal degeneration.
3.3. Failure of an Exquisite Networkof Quality Control in PD?.
An early study by de Mattos and coworkers [107]i nb r a i n s
from PD patients demonstrated mitochondrial tumefaction
and depositsofamorphous substanceintomitochondria and
axons distinctively absent in the control patients. Consistent
ﬁndings were further found by Trimmer and colleagues
[108] in PD cybrids and in studies with the same model
in our laboratory. Mitochondria in PD cybrid cells were
found enlarged or swollen with disrupted cristae and a
discontinuous outer membrane [16]. In contrast, sublethal
concentrations of MPP+ and rotenone, two mitochondrial
complex I inhibitors that induce parkinsonian syndrome
in vivo, were shown to promote Drp1-dependent mito-
chondrial fragmentation [109], to decrease mitochondrial
mobility [110, 111] and to disrupt microtubule dynamics
[112–114]. However, chronic low-dose exposure to rotenone
and MPP+ was shown to induce mitochondria swelling
and decreased anterograde transport of mitochondria and
vesicles, probably due to a reduction of ATP supply to
molecular motors [110, 115].
Additional studies of mammalian PINK and parkin
models have been suggestive of their involvement on the
regulation of mitochondrial turnover, dynamics, and cellular
homeostasis. The role for parkin was revealed using a
Drosophila parkin null mutant or by overexpression of one
pathogenic parkin mutation, showing severe mitochondrial
pathology, reduced lifespan, and increased apoptosis [116,
117]. It was also found that functional parkin is necessary
for proper mitochondrial organization and morphology
throughout spermatid development in Drosophila [118].
Additionally,mitochondrialrespiratory defectsandmorpho-
logical abnormalities have been reported in brains of parkin-
knockout, parkin-mutant transgenic mice [119, 120], and in
leukocytes from PD patients with parkin mutations [121,
122]. Primary ﬁbroblasts from patients carrying mutations
in parkin, or control ﬁbroblasts treated with siRNA against
parkin, revealed lower mitochondrial membrane potential,
lower ATP levels, and increased susceptibility to rotenone
toxicity [121]. The ﬁbroblasts also exhibited mitochondrial
morphological abnormalities, exhibiting mitochondria that
were longer and more highly branched. Interestingly, there
was a relationship between those mitochondrial deﬁcits and
increased length and branching, as well as between reduced
complex I activity and mitochondrial branching. Thus, as
parkin is not speciﬁcally located into mitochondria and
must be translocated to this organelle, it is conceivable that
its eﬀects on mitochondrial morphology are tied into a
larger pathway that mediates mitochondrial maintenance.
Actually, within mitochondria, parkin mainly localizes in
the inner membrane and matrix, where it has been shown6 Parkinson’s Disease
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Figure 1: Potential susceptibility of neurons to mitochondrial dysfunction and impaired mitochondrial turnover. (Wild type)I nh e a l t h y
neurons, mitochondria, prosurvival signals associated to signaling endosomes, and autophagomes enclosing damaged organelles or protein
aggregates are able to travel long distances from the cell periphery to perinuclear region in the cell body, where most lysosomes are
concentrated. (No transport) Disruption of microtubule network and subsequent defects on retrograde transport prevent the proper
distribution of mitochondria and the eﬃcient transport of autophagy substrates towards lysosomes for degradation, which can lead to
defects in energy supply and cargos clearance by autophagy. (No mitophagy) Blockage of autophagic activity seems to be responsible
for the accumulation of damaged mitochondria, toxic protein products, aggregates, and leaking autophagic vesicles, all of which have a
negative eﬀect on neuronal functioning and survival, precipitating the “dying-back”-type of axonal degeneration. (No fusion)T h ea b s e n c e
of mitochondrial fusion may result in an accumulation of damaged mitochondria or decreased healthy mitochondria at the nerve terminal.
Mitochondria secondarily have defects in motility that prevent proper distribution within the axon and in the periphery. (No ﬁssion)I n
the absence of mitochondrial ﬁssion, most of the mitochondrial population is extensively long and interconnected, and a subset shows
ultrastructural defects and dysfunction. The large mitochondria clusters within dendrites are not eﬃciently transported and/or engulfed by
autophagosomes towards cell body for lysosomal degradation. (MT: microtubule tracks oriented along the axon with plus (+) ends distal
and (−) ends proximal to the cell body).
to enhance transcription and replication of mtDNA and
to induce mitochondrial proliferation [123]. This eﬀect
seems to be mediated by the interaction of parkin with
mitochondrial transcription factor A (TFAM), a protein
that regulates mtDNA transcription by directly binding and
coating mtDNA [123]. In PC12 cells diﬀerentiated into
neurons by nerve growth factor, parkin was located in the
outer mitochondrial membrane, where prevented ceramide-
induced mitochondrial swelling, cytochrome c release, cas-
pase activation, and apoptotic cell death [124]. This eﬀect
may be related to the above-mentioned ability of parkin to
regulate mitochondrial morphology. Intriguingly, complex
I inhibition with rotenone seems to induce the release of
mitochondrial parkin to the cytosol [123]. In light of these
results,complexIdeﬁciencyorloss-of-function mutationsin
parkin may impair the mitochondrial localization of parkin
and thus abolish the boosting and beneﬁcial eﬀects of this
protein at the mitochondria. Indeed, the protective eﬀect
of Parkin is abolished by PD-causing parkin mutations and
proteasome inhibitors, indicating that itis mediated by its E3
ubiquitin ligase activity [124].
Regarding PINK, a signiﬁcant decrease in mitochondrial
respiration in the striatum of PINK1 knockout mice [125]
was observed. Several groups also described mitochondrial
abnormalities in pink Drosophila mutants, similar to those
of parkin mutant Drosophila [126–128]. Moreover, the
protective eﬀect of PINK1 has also been conﬁrmed in
primary neuronal cultures and in an in vivo mouse model
of PD [129]. In this study, PINK1 suppression by small
interfering RNA in primary cortical neurons treated with
MPP+ promoted neuronal death, while overexpression of
wild-type PINK1 protected these neurons against MPP+
toxicity [129]. The protective eﬀect of PINK1 was conﬁrmed
as being mediated by its kinase domain and was abolished
in PD-related PINK1 mutants [129]. Adenoviral-mediated
expression of PINK1 in mice SNpc protected dopaminergic
neurons from MPTP-induced cell death, an eﬀect that was
abolished by expression of kinase-inactive PINK1 mutants
[129]. Surprisingly, the mitochondrial targeting sequence
and the mitochondrial localization of PINK1 were not
necessary for its protective eﬀect, either in vitro or in
vivo, as demonstrated in a mutant PINK1 with impairedParkinson’s Disease 7
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Figure 2: Rationale for the contribution of mitochondrial dysfunction to synaptic degeneration in sporadic PD. Mitochondrial dysfunction
induced by a complex I defect leads to alterationsin mitochondria-dependent metabolism (reduced ATP levels anddecreased mitochondrial
inner membrane potential). This bioenergetic failure seems to potentiate microtubule network breakdown. Subsequently, when the
dynamics and functional integrity of microtubules are compromised, changes in anterograde and retrograde ﬂux along the axon can be
impaired. Cargos that are actively transported along the axon include mitochondria, autophagosomes, and proteins. Moreover, a decrease
in mitochondrial membrane potential deregulates calcium homeostasis, which leads to the overactivation of calpains. Calpains are key
regulators of mitochondrial fusion, since they impair Opa1 proper function. Alterations in fusion/ﬁssion events promote mitochondrial
enlargement, which can impair their removal by mitophagy. Indeed, the accumulation of protein aggregates, autophagosomes,and enlarged
deﬁcient mitochondria in presynaptic termini is observed at early stages of PD. Our hypothesis implies that mitochondrial metabolism
impairment could be responsible for synaptic degeneration in PD. (∗Indicates that mutated or overexpressed α-synuclein could induce
mitochondrial dysfunction and that loss-of-function of Parkin or/and PINK1 can deregulate mitochondrial mitophagy.)
mitochondrial localization [129]. These results indicate that
cytoplasmic, rather than mitochondrial, kinase activity of
PINK1 is critical for its protective eﬀect. To reconcile these
results with the known mitochondrial localization of PINK1,
it has been reported that while PINK1 spans the outer
mitochondrial membrane, with the N-terminal end inside
the mitochondria, the C-terminal kinase domain of PINK1
actually faces the cytosol [130]. Very recently, it was also
suggested that PINK1 may also be involved in mitochondrial
transport. Weihofen and colleagues demonstrated that Miro
and Milton overexpression reverted mitochondria pathology
induced by the loss of functional PINK1 [131]. Moreover,
PD-associated PINK1 mutations also compromise the selec-
tive degradation of depolarized mitochondria maybe due to
a decreased physical binding of PINK1to Parkin. In addition
to an impaired PINK1 kinase activity, reduced binding of
PINK1 to Parkin leads to failure in mitochondrial clearance,
resulting in the accumulation of damaged mitochondria
[132].
Both Drosophila and mammalian cells studies show
that loss of PINK result in abnormalities in mitochondrial
morphology, involving mitochondrial swelling accompanied
by decreased or disorganized cristae [125, 133], which are
remarkably similar to mitochondria in sporadic PD cybrid
cell lines [16, 108, 134]. Interestingly, PINK and Parkin
ﬂ i e sw e r es h o w nt oh a v ec o m p a r a b l ep h e n o t y p e s .W h i l e
parkin overexpression reverses the eﬀects of PINK loss-of-
function on mitochondrial morphology, the opposite was
not observed, suggesting that parkin acts downstream of
PINK [126, 128].
However, studies in PD patients ﬁbroblasts carrying
PINK mutations and in human HeLa, M17, and SH-SY5Y
PINK knockdown cells showed an increase in fragmented
mitochondria [135, 136]. These results may be correlated
with the role of PINK in preventing mitochondrial oxidative
stress and ﬁssion events. Indeed, an increase in mitochon-
drial fragmentation wasreversedby overexpression ofParkin
inHeLaandSH-SY5Ycells,whichindicatesaclearanceofthe
damaged mitochondria.
Foremost, silencing PINK expression in dopaminergic
SH-SY5Y cells resulted in progressive loss of mitochon-
drial function characterized by decreased mtDNA levels,
impaired oxidative phosphorylation, and oxidative stress
[137]. Nevertheless, in this study the decreases in mtDNA8 Parkinson’s Disease
and oxidative phosphorylation do not appear to be directly
related to Parkin loss of function. Instead, loss of mtDNA
canbesuggestedasthemostprobablecauseofmitochondrial
respiratory chain inhibition and consequent oxidative stress.
This supports the notion that the combination of both
mitochondrial dysfunction and perturbed PINK1 activity
increases the susceptibility to oxidative stress or apoptosis as
has been reported in brain cells [125, 138]. Besides, PINK
knockdowncellsshow decreased phosphorylationofDrp1 at
S637 through activation of calcineurin phosphatase activity
[136]. While PINK overexpressing cells show Drp1 2D-
gel mobility consistent with higher phosphorylation states
[139]. Because Drp1 phosphorylation at S637 inhibits its
ability to mediate ﬁssion [52], these results point to a role
of PINK as a ﬁssion suppressor.
Even though PINK1/Parkin may regulate mitochondrial
dynamics in some of the familial PD forms, it seems evident
that mitochondrial physiology is the major determinant of
mitochondria morphology in sporadic cases. Particularly,
it is believed that the structural composition of mito-
chondria may determine their propensity for fragmentation
and self-elimination, and that this may be inﬂuenced by
the metabolic status within the cell. Accordingly, an RNAi
screening for mitochondrial proteins in Caenorhabditis ele-
gans demonstrated that the knockdownofmore than 80% of
mitochondrial genes lead to mitochondrial fragmentations
and/oraggregation, showing that mitochondria morphology
maintenance requires a huge number of proteins and not
necessarily the speciﬁc action of mitochondrial fusion or
ﬁssion machinery [140].
Furthermore, ultrastructural examination indeed re-
vealed “autophagic stress” in melanized neurons of the SNpc
in PD patients [141]. Moreover, accumulated autophago-
somes have been observed in human PD nigral neurons
[141], but not in nigral neurons during normal aging.
Alterations in macroautophagy are also implicated in PD
since its inhibition leads to wt α-synuclein accumulation,
suggesting that this lysosomal pathway is also involved in
normal α-synuclein turnover [142]. Very recently, it was
also demonstrated that α-synuclein overexpression impairs
macroautophagy in mammalian cells and in transgenic
mice [143]. Interestingly, recent work in our laboratory has
shown that cells with an mtDNA-mediated mitochondrial
dysfunction have enhanced formation autophagic vacuoles
but present decreased degradation ability, suggesting that
the autophagic clearance is impaired in PD. We have
also observed that macroautophagy inhibition increased
α-synuclein oligomerization and prompts apoptosis (DM
Ardu´ ıno, unpublished data).
4.ConcludingRemarksand Perspectives
There is a growing body of evidence supporting that alter-
ations in mitochondrial dynamics are implied in PD patho-
genesis(Figure 1).However,therearestillsomecontroversies
among the diﬀerent models of disease, namely, concerning
themitochondrial morphologychanges and the mechanisms
that control mitochondrial shape and function. Common
approaches, such as those modulating fusion/ﬁssion, are
scarce to explain how mitochondrial abnormalities occur
in certain disease states. Undoubtedly, it seems evident that
cellularphysiologyisthemajordeterminantofmitochondria
function and morphology. In addition,mitochondrial fusion
and ﬁssion are not isolated in the cell and other intrinsic
cellular alterations, such as impaired vesicular traﬃcking
and axonal transport, intracellular degradation systems and
mitochondrial metabolism, have also been described in PD
and could further alter mitochondrial biogenesis, turnover,
and maintenance.
Takenin accounttheavailabledata,we proposethemito-
chondrial cascade hypothesis to explain PD pathogenesis.
Mitochondrial dysfunction induced by a complex I defect
leads to alterations in mitochondrial-dependent metabolism
(reduced ATP levels and decrease in mitochondrial mem-
brane potential) [144]. This bioenergetic failure seems to
play a role in microtubule network breakdown [145].
Subsequently, when microtubules dynamic and functional
integrity are compromised, changes in anterograde and
retrograde ﬂux along the axon can lead to defects in the
supply and clearance of mitochondria [146]. Moreover, a
decrease in mitochondrial membrane potential potentiates
an increase in cytosolic calcium which leads to calpains
overactivation [147]. In addition, mitochondria with low
inner membrane potential have a decrease in Opa1 levels
and do not fuse [148]. Accordingly, calpain activation seems
to mediate Opa1 loss of function [149]. Together, these
ﬁndings point to an accumulation of enlarged mitochondria
[16], that will impair eﬃcient removal by autophagy. Our
hypothesis implies that mitochondrial failure may be the
initial eventin sporadic PD, although it has a prominent role
in some of PD familial forms (Figure 2).
Understanding this complex molecular network and
indentifying the factors that control all of these interrelated
mechanisms is currently a priority and a challenge for future
studies.
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